Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2011  |  Volume : 7  |  Issue : 4  |  Page : 442--447

Efficacy and safety of concurrent chemoradiation with weekly cisplatin ± low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: A phase II-III clinical trial


Mohammad Mohammadianpanah1, Sasan Razmjou-Ghalaei2, Amin Shafizad3, Yaghoub Ashouri-Taziani1, Bijan Khademi4, Niloofar Ahmadloo1, Mansour Ansari1, Shapour Omidvari1, Ahmad Mosalaei5, Mohammad Amin Mosleh-Shirazi1 
1 Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Radiation Oncology, Golestan Hospital, Ahwaz University of Medical Sciences, Ahwaz, Iran
3 Department of Radiation Oncology, Hormaozgan University of Medical Sciences, Bandar Abbass, Iran
4 Department of Otolaryngology, Head and Neck Surgery, Khalili Hospital and Cancer Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
5 Department of Radiation Oncology, Namazi Hospital and Cancer Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Correspondence Address:
Mohammad Mohammadianpanah
Department of Radiation Oncology, Cancer Research Center, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz 71936-11351
Iran

Background: This is the first study that aimed to determine the efficacy and safety of concurrent chemoradiation with weekly cisplatin ± celecoxib 100 mg twice daily in locally advanced undifferentiated nasopharyngeal carcinoma. Materials and Methods: Eligible patients had newly diagnosed locally advanced (T3-T4, and/or N2-N3, M0) undifferentiated nasopharyngeal carcinoma, no prior therapy, Karnofsky performance status ≥ 70, and normal organ function. The patients were assigned to receive 7 weeks concurrent chemoradiation (70 Gy) with weekly cisplatin 30 mg/m 2 with either celecoxib 100 mg twice daily, (study group, n = 26) or placebo (control group, n = 27) followed by adjuvant combined chemotherapy with cisplatin 70 mg/m 2 on day 1 plus 5-fluorouracil 750 mg/m 2 /d with 8-h infusion on days 1-3, 3-weekly for 3 cycles. Results: Overall clinical response rate was 100% in both groups. Complete and partial clinical response rates were 64% and 36% in the study group and 44% and 56% in the control group, respectively (P > 0.25). The addition of celecoxib to concurrent chemoradiation was associated with improved 2-year locoregional control rate from 84% to 100% (P = 0.039). Conclusions: The addition of celecoxib 100 mg twice daily to concurrent chemoradiation improved 2-year locoregional control rate.


How to cite this article:
Mohammadianpanah M, Razmjou-Ghalaei S, Shafizad A, Ashouri-Taziani Y, Khademi B, Ahmadloo N, Ansari M, Omidvari S, Mosalaei A, Mosleh-Shirazi MA. Efficacy and safety of concurrent chemoradiation with weekly cisplatin ± low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: A phase II-III clinical trial.J Can Res Ther 2011;7:442-447


How to cite this URL:
Mohammadianpanah M, Razmjou-Ghalaei S, Shafizad A, Ashouri-Taziani Y, Khademi B, Ahmadloo N, Ansari M, Omidvari S, Mosalaei A, Mosleh-Shirazi MA. Efficacy and safety of concurrent chemoradiation with weekly cisplatin ± low-dose celecoxib in locally advanced undifferentiated nasopharyngeal carcinoma: A phase II-III clinical trial. J Can Res Ther [serial online] 2011 [cited 2020 Aug 11 ];7:442-447
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2011;volume=7;issue=4;spage=442;epage=447;aulast=Mohammadianpanah;type=0